Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 May 2025
Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco Vizeacoumar (Ph.D.) and Dr. Andrew Freywald (Ph.D.) with USask and the Saskatchewan Cancer Agency.
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
Sub-Q Ketamine is Safe and Very Effective for Severe Depression.
2.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
3.
Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.
4.
Can Concurrent Boost Safely Shorten Breast Cancer Radiation?
5.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
1.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
2.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
3.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
4.
Polycythemia Vera: A Historical Perspective and Contemporary Management
5.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge